8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

10x Genomics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39035	45-5614458
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6230 Stoneridge Mall Road

Pleasanton, California 94588

(925) 401-7300

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class A common stock, par value $0.00001 per share	TXG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.07 Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders of 10x Genomics, Inc. (the "Company") was held on June 11, 2024, via live webcast (the “Annual Meeting”). At the Annual Meeting, there were present, virtually or by proxy, holders of 112,157,824 shares of the Company's Class A and Class B common stock, representing 229,232,830, or approximately 93.10%, of the 246,219,923 eligible votes, constituting a quorum. The matters submitted to a vote at the Annual Meeting and the final voting results of such matters were as follows:

Proposal 1 - Election of Directors

The Company’s stockholders approved the election of one Class II director to hold office for a three-year term expiring at the Company’s 2027 annual meeting of stockholders or until her respective successor has been duly elected and qualified or until her earlier resignation or removal. The final voting results were as follows:

Nominee	Votes For	Votes Against	Abstentions	Broker Non-Votes
Kimberly J. Popovits	198,553,136	18,689,301	125,755	11,864,638

Proposal 2 - Ratification of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2024. There were no broker non-votes on this proposal. The final voting results were as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes
228,845,897	174,119	212,814	—

Proposal 3 - Vote to Approve an Amendment to the Company's Amended and Restated Bylaws to Permit the Company's Board of Directors to Amend the Company's Amended and Restated Bylaws Without Requiring Stockholder Approval

The Company’s stockholders did not approve a proposed amendment to the Company's amended and restated bylaws to permit the Company's Board of Directors to amend the Company's amended and restated bylaws without requiring stockholder approval. The final voting results were as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes
112,727,437	104,506,389	134,366	11,864,638

Proposal 4 - Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers

The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 26, 2024. The final voting results were as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes
180,775,070	36,417,839	175,283	11,864,638

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	10x Genomics, Inc.
	By:	/s/ Eric S. Whitaker
	Name:	Eric S. Whitaker
	Title:	Chief Legal Officer
Date: June 13, 2024

XML

Cover	Jun. 11, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	Jun. 11, 2024
Entity Registrant Name	10x Genomics, Inc.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-39035
Entity Tax Identification Number	45-5614458
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A common stock, par value $0.00001 per share
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Amendment Flag	false
Entity Central Index Key	0001770787